

June 25, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Press Release

Ref: Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed herewith the Press Release titled “*Dr. Lal PathLabs strengthens its genomics capabilities with Illumina’s NovaSeq X Series*”.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer



PRESS RELEASE

Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series

New Delhi, June 25, 2025: Dr. Lal PathLabs Limited ("DLPL"), one of India's most trusted diagnostic chains, has expanded its genomics capabilities by adding Illumina's NovaSeq™ X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights.

The NovaSeq™ X system features Illumina's cutting-edge XLEAP-SBS™ chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements.

"With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence," said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. "This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape."

Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing ("NGS"), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.

"At Genevolve, our mission has always been to push the boundaries of genomic innovation. Bringing the NovaSeq X Series into our portfolio is a testament to that commitment, combining the power of next-generation sequencing and AI to enable faster, more precise, and meaningful insights for better outcomes," said Dr. Vandana Lal, Executive Director, Dr. Lal PathLabs Limited.

"As Illumina continues to grow in India, we are committed to democratizing access to sequencing technologies". Said Gregory Essert, General Manager, Emerging Markets, Illumina. NovaSeq X Series represents our leadership in next-generation sequencing, and we are pleased to see it being adopted by institutions like Dr. Lal PathLabs, which are at the forefront of driving scientific discovery and access to genomic insights in India. We hope this empowers them to reach their goals more quickly."

"Our longstanding vision has been to accelerate India's adoption of next-generation sequencing technologies. We are proud to support Dr. Lal PathLabs in integrating the NovaSeq X platform into their genomics ecosystem, driving transformative research and innovation," said Praveen Gupta, Managing Director, Premas Life Sciences.

Dr. Lal PathLabs Limited and Illumina aim to engage closely with India's medical and scientific communities to build awareness and capacity for genomics-based decision-making.

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2025 the Company has 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit [illumina.com](https://www.illumina.com) and connect with us on [X](#), [Facebook](#), [LinkedIn](#), [Instagram](#), [TikTok](#), and [YouTube](#).

MEDIA CONTACTS:

Chehak Mishra – Adfactors PR (Dr Lal PathLabs)

Phone: +91 8505824666

Email: Chehak.mishra@adfactorspr.com

Aarti Deepak Taneja – Illumina Inc.

Phone: 91 7291988760

Email: ataneja@illumina.com

Sonali Singh - Weber Shandwick (Illumina)

Phone: 91 9591845834

Email: SSingh@webershandwick.com